Setting Up a Medical-Device Import and Distribution Business in the UAE

With medical devices the regulatory load is set product by product: each device's class fixes the evidence expected, the registration path, the handling standard and the vigilance duties, while the company itself needs establishment-level standing to import and represent at all. The entity is a container; classification decides what it must be able to hold.

A trading company can be perfectly formed and still unable to land a shipment, because the devices behind the invoice are unregistered, their manufacturer has no local representative, or a screening app in the catalogue is in fact a regulated diagnostic. The useful question is not which licence sells fastest. It is what each product's intended purpose makes it in the regulator's eyes — and which entity then answers for it from import through to field safety.

Start by choosing which of these models most closely describes the plan:

If more than one applies, note that these roles carry different duties for the same physical product: the representative answers to the authority for the manufacturer, the importer for the shipment, the distributor for storage and supply, the brand owner for the claims. A group can hold several roles across entities, but every duty must land on exactly one of them — a portfolio where representation and import sit in different companies with no contract between them is a vigilance failure waiting for its incident. For those considering diversification, establishing a cosmetics, fragrance or personal-care brand in the UAE might be an attractive option.

Because the duties are set per device rather than per company, test these before a jurisdiction or activity is selected:

Not every line bites every model — a consumables distributor and an implant importer live at opposite ends of the effort scale. What the list forbids is answering by label: calling a diagnostic algorithm a wellness app, or a monitoring platform ordinary software, does not reclassify it if the intended purpose is medical.

Conclude the stage with a written portfolio position: each device, its intended purpose and expected class, its manufacturer and representative, who imports and stores it, and which new claim, feature or software update would change its class. That document steers the registrations, the manufacturer agreements and every later conversation with banks and hospital buyers. If expanding into other sectors, consider the requirements for a nutraceutical or dietary-supplement company in the UAE.

The portfolio's classes drive the entity decision, so define these variables before comparing options like setting up a mainland company, free-zone and financial-centre routes:

The entity contracting with hospitals and clinics should hold the establishment standing, the product registrations and the vigilance capability its contracts assume — and if it installs or services devices, the trained engineers as well. Representation vehicles and overseas parents can carry other roles legitimately, but a structure optimised for a cheap start and silent on who files an adverse-event report will be rebuilt under pressure, which is the expensive way to build anything.

Device budgets scale with risk class — the dossier for an implant is a different animal from a box of consumables — so layer the numbers:

The schedule is owned by the registration queue, class by class: low-risk lines may clear while a high-class device is still assembling its evidence, and a software update can reopen a file that was closed. Launch the portfolio in class order rather than waiting for the slowest device — and never read the incorporation date as a launch date.

A bank, insurer or hospital procurement team underwriting a device business is really underwriting its registration and vigilance file: proof that every product on the price list is classified, registered, represented and traceable. Prepare the following before onboarding begins:

Hospital and laboratory tenders will test this file harder than the bank does — they ask for the registration evidence, the authorisation chain and the field-safety procedure before any purchase order. When the catalogue, the registrations and the manufacturer letters all reconcile, both reviews move faster. Nothing in the file guarantees an account, a tender win or an approval.

Each open question maps to a duty that will exist whether or not anyone accepted it — vigilance and representation do not wait for the org chart. Record the assumption, name its verifier, and close it before stock or software ships.

The expensive failure here is the misclassified product — most often software — sold for months on a trading licence until an incident or an audit reveals it was a regulated device all along, with no registration, no representative and no vigilance trail. Compare setup routes by how safely they carry the whole intended portfolio, not by the incorporation invoice.

Velarozone’s adviser-led assessment turns a device portfolio into a classification-led setup decision. Depending on the facts, the written plan can cover:

The final authority shortlist, exact activity selection, current requirements and filing path are confirmed against the live facts. They are decision outputs, not website claims.